about
Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the ratLack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine releaseAnalysis of chiral amino acids in cerebrospinal fluid samples linked to different stages of Alzheimer disease.Alterations in brain leptin signalling in spite of unchanged CSF leptin levels in Alzheimer's disease.Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer's disease brain.Cardiotrophin-1 is a key regulator of glucose and lipid metabolism.Aggregation of the Inflammatory S100A8 Precedes Aβ Plaque Formation in Transgenic APP Mice: Positive Feedback for S100A8 and Aβ Productions.ALS: A bucket of genes, environment, metabolism and unknown ingredients.Insights into the mechanisms of copper dyshomeostasis in amyotrophic lateral sclerosis.Estrogen protects against amyloid-β toxicity by estrogen receptor α-mediated inhibition of Daxx translocation.Neonatal stress affects vulnerability of cholinergic neurons and cognition in the rat: involvement of the HPA axis.Increase of locomotor activity underlying the behavioral disinhibition in tg2576 mice.Altered NCAM expression associated with the cholinergic system in Alzheimer's disease.Facilitation of cholinergic transmission by combined treatment of ondansetron with flumazenil after cortical cholinergic deafferentation.Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease.Adrenomedullin Contributes to Age-Related Memory Loss in Mice and Is Elevated in Aging Human Brains.Effects of chronic blockade of 5-HT(6) receptors on NMDA receptor subunits expression.Involvement of an altered 5-HT -{6} receptor function in behavioral symptoms of Alzheimer's disease.Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease.Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice.Long-lasting behavioral effects and recognition memory deficit induced by chronic mild stress in mice: effect of antidepressant treatment.Increased Levels of Brain Adrenomedullin in the Neuropathology of Alzheimer's Disease.Resistance training does not have an effect on cognition or related serum biomarkers in nonagenarians: a randomized controlled trial.Modulation of BDNF cleavage by plasminogen-activator inhibitor-1 contributes to Alzheimer's neuropathology and cognitive deficits.Combination of apolipoprotein E4 and high carbohydrate diet reduces hippocampal BDNF and arc levels and impairs memory in young mice.Mineralocorticoid receptor activation induces insulin resistance through c-Jun N-terminal kinases in response to chronic corticosterone: cognitive implications.Down-regulation of glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer's disease.Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease.Maternal imprinting on cognition markers of wild type and transgenic Alzheimer's disease model mice.Reduced Adrenomedullin Parallels Microtubule Dismantlement in Frontotemporal Lobar Degeneration.Clinical evidences supporting the Src/c-Abl pathway as potential therapeutic target in amyotrophic lateral sclerosisAdrenomedullin, a Novel Target for Neurodegenerative DiseasesAmyotrophic lateral sclerosis: a complex syndrome that needs an integrated research approachUpregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer's diseaseRetinoids and Amyotrophic Lateral Sclerosis
P50
Q24651957-C1F69EC5-AD43-4CA0-A9CC-F2759A3369B5Q28575664-6AE8A957-D9C3-4E68-99CE-B2FE21BE3B89Q34044474-15994504-2E12-429E-AA95-D1646FE9552FQ35080530-22E9D8A9-BAE0-4BD4-8EE7-C6089C0188A6Q36379547-7BD85293-08DF-4B47-8F5C-2B306F896824Q38333002-9607A310-943D-4ACB-829E-2B39A3D8600CQ38774270-D573B38B-0D2B-48F8-A211-329280ACEE88Q38847081-9CFD7553-5DA4-44EC-A0A5-DCB6EB9E43BAQ39361708-7F4805DD-075B-44AB-AA26-9F493CEE9032Q39437122-01C01E82-E4F0-4FBF-8802-B4B2AE83153AQ42455023-19BC11E5-6A86-43EE-B100-DF0E345DD511Q42618768-D37839E3-C1DC-4BB3-B699-55999C5599D9Q43158595-10139321-9B03-4A9D-A0F4-C8D704F94164Q44956213-140CA697-1455-46BB-A2EC-BED74FA28889Q45262354-161564CD-1382-4833-BC06-9CC63DDD5665Q45406965-715B0A9B-A60A-4E28-912A-CA20961F5225Q45978812-886F9A8D-2447-4E07-BD93-979B9D20F2AAQ46558596-508A79FF-8485-49C4-95A2-A6DF870B3637Q46582617-7449C6D9-9904-4EA4-89A6-DF737480114EQ46591781-B255AD0B-6A18-444B-9140-76E5CF7ED9B4Q46602527-DD1051BA-A54B-4E91-AAD2-DE6C9DFFFA52Q47863897-32ED513E-6B8A-47A6-BEE3-E9C5FA9F28C9Q48188960-64EACE8A-F5F2-4ACB-9286-621277C3C15FQ48334323-471E54B7-E650-4408-9907-C9D15B3C23C2Q48427496-1C9A0D4C-FA96-48E5-BC56-C77769885083Q48572803-72C06C30-5ABB-4FF8-81F3-FB3E417E50E3Q48696116-CFC82303-DAE0-4C2D-801C-B45A0CC1BA30Q51037302-A02368F9-8E70-4491-898E-877C7EF7572AQ52565458-570A1D9F-DABE-4CAC-8F9B-3C30F82D087EQ52691494-26078C38-E2EC-4757-B89B-C7FC8C354383Q57464870-899E69E8-7084-47A3-A452-AAA27EF977D2Q59543627-EA9402FD-6FB6-4D14-B5D0-BEE8DB9CE64DQ61804461-925D5F33-F660-4E8E-A8FA-B8461CCEC28DQ83378749-E80EE6AC-E134-4EFE-BF25-02D5B90DED35Q90932567-78FDCB7E-F753-4117-B2C2-8266B50CB090
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Francisco J Gil-Bea
@en
Francisco J Gil-Bea
@nl
type
label
Francisco J Gil-Bea
@en
Francisco J Gil-Bea
@nl
prefLabel
Francisco J Gil-Bea
@en
Francisco J Gil-Bea
@nl
P31
P496
0000-0002-1449-6233